Impacting News
Premium
ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer
Innovent Biologics Announcement at ASCO Innovent Biologics , Inc. ( HKEX: 01801 )(OTC: IVBXF ) announced that the clinical data of a randomized controlled Phase 1b study evaluating IBI310 (anti-CTLA-...
P
Prohost Biotech
1 min read
2
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion